Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study)

被引:4
|
作者
Kamiya, Koji [1 ]
Saeki, Hidehisa [2 ]
Tokura, Yoshiki [3 ,4 ]
Yoshihara, Shigemi [5 ]
Sugai, Junichi [6 ]
Ohtsuki, Mamitaro [1 ]
机构
[1] Jichi Med Univ, Dept Dermatol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan
[2] Nippon Med Sch, Dept Dermatol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
[3] Chutoen Gen Med Ctr, Allerg Dis Res Ctr, 1-1 Shobugaike, Kakegawa, Shizuoka 4368555, Japan
[4] Chutoen Gen Med Ctr, Dept Dermatol & Skin Oncol, 1-1 Shobugaike, Kakegawa, Shizuoka 4368555, Japan
[5] Dokkyo Med Univ, Dept Pediat, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan
[6] Sugai Dermatol Parkside Clin, 6-7-7 Motoimaizumi, Utsunomiya, Tochigi 3210954, Japan
关键词
atopic dermatitis; pediatric; proactive therapy; rank-down therapy; topical corticosteroids; FLUTICASONE PROPIONATE CREAM; DOUBLE-BLIND; GUIDELINES; MANAGEMENT; RELAPSE; EMOLLIENT; CHILDREN; MODERATE; RISK; 0.05-PERCENT;
D O I
10.3390/jcm11216477
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Topical corticosteroids are used as first-line treatment for atopic dermatitis (AD). Regarding the maintenance of remission achieved by topical corticosteroids, no previous studies have compared proactive therapy with rank-down therapy. We compared their efficacy and safety in Japanese children with moderate to severe AD. Patients who had achieved remission with a very strong topical corticosteroid were randomized to 4-week maintenance treatment with either intermittent use of the same drug (proactive therapy) or daily use of a strong topical corticosteroid for 1 week followed by daily use of a medium-potency topical corticosteroid for 3 weeks (rank-down therapy); 49 patients were randomized (proactive therapy, n = 24; rank-down therapy, n = 25). During maintenance treatment, the relapse rate was 8.33% in the proactive therapy group and 20.0% in the rank-down therapy group (p = 0.0859). The mean (+/- standard deviation) itching score on a numerical rating scale in the rank-down therapy group increased significantly from 2.5 +/- 1.9 to 3.6 +/- 2.6 (p = 0.0438). Adverse events occurred in 2 patients receiving proactive therapy and 3 patients receiving rank-down therapy. Proactive therapy appears to be as safe as rank-down therapy and may be more effective for itch in pediatric AD in remission.
引用
收藏
页数:11
相关论文
共 45 条
  • [21] Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study
    Arnold, Lesley M.
    Whitaker, Susan
    Hsu, Ching
    Jacobs, David
    Merante, Domenico
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (10) : 1825 - 1835
  • [22] Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study
    Landis, Megan N.
    Arya, Mark
    Smith, Stacy
    Draelos, Zoe
    Usdan, Lisa
    Tarabar, Sanela
    Pradhan, Vivek
    Aggarwal, Sudeepta
    Banfield, Christopher
    Peeva, Elena
    Vincent, Michael S.
    Sikirica, Vanja
    Xenakis, Jason
    Beebe, Jean S.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 878 - 887
  • [23] Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
    Kim, Jeong Mi
    Kim, Sang Soo
    Kim, Jong Ho
    Kim, Mi Kyung
    Kim, Tae Nyun
    Lee, Soon Hee
    Lee, Chang Won
    Park, Ja Young
    Kim, Eun Sook
    Lee, Kwang Jae
    Choi, Young Sik
    Kim, Duk Kyu
    Kim, In Joo
    DIABETES & METABOLISM JOURNAL, 2020, 44 (01) : 67 - 77
  • [24] Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study
    Chopra, Arvind
    Chandrashekara, S.
    Iyer, Rajgopalan
    Rajasekhar, Liza
    Shetty, Naresh
    Veeravalli, Sarathchandra Mouli
    Ghosh, Alakendu
    Merchant, Mrugank
    Oak, Jyotsna
    Londhey, Vikram
    Barve, Abhijit
    Ramakrishnan, M. S.
    Montero, Enrique
    CLINICAL RHEUMATOLOGY, 2016, 35 (04) : 1059 - 1064
  • [25] Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study
    Choi, Seong Hye
    Park, Kyung Won
    Na, Duk L.
    Han, Hyun Jeong
    Kim, Eun-Joo
    Shim, Yong S.
    Lee, Jae-Hong
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (07) : 1375 - 1383
  • [26] Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: An open-label, randomized, parallel-group study
    Tanaka, Shinya
    Yoshida, Akira
    Kono, Shinjiro
    Ito, Manabu
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2017, 22 (03) : 536 - 541
  • [27] Comparative Effectiveness of Cheonwangbosimdan (Tian Wang Bu Xin Dan) Versus Cognitive-Behavioral Therapy for Insomnia in Cancer Patients: A Randomized, Controlled, Open-Label, Parallel-Group, Pilot Trial
    Moon, Sun-Young
    Jerng, Ui Min
    Kwon, O-Jin
    Jung, So-Young
    Lee, Jee Young
    Yoon, Seong Woo
    Shin, Won-Chul
    Byun, Jung-Ick
    Lee, Jun-Hwan
    INTEGRATIVE CANCER THERAPIES, 2020, 19
  • [28] Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study
    Arzimanoglou, Alexis
    Ferreira, Jose A.
    Satlin, Andrew
    Mendes, Shannon
    Williams, Betsy
    Critchley, David
    Schuck, Edgar
    Hussein, Ziad
    Kumar, Dinesh
    Dhadda, Shobha
    Bibbiani, Francesco
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2016, 20 (03) : 393 - 402
  • [29] Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study
    Seol, Young Mi
    Kim, Hyo Jeong
    Choi, Young Jin
    Lee, Eun Mi
    Kim, Yang Soo
    Oh, Sung Yong
    Koh, Su Jin
    Baek, Jin Ho
    Lee, Won Sik
    Joo, Young Don
    Lee, Hyun Gi
    Yun, Eun Young
    Chung, Joo Seop
    SUPPORTIVE CARE IN CANCER, 2016, 24 (02) : 945 - 952
  • [30] Rationale and design of MANJUSRI trial: A randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS
    Lu, Wenbin
    Chen, Lijuan
    Wang, Yu
    Yao, Yuyu
    Fu, Cong
    Zuo, Pengfei
    Ma, Genshan
    CONTEMPORARY CLINICAL TRIALS, 2015, 40 : 166 - 171